首页> 美国卫生研究院文献>Medical Gas Research >Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection
【2h】

Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection

机译:缺血性卒中中组织纤溶酶原激活物和高压氧的共同给药:神经保护的持续希望

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intravenous recombinant tissue-type plasminogen activator (r-tPA, alteplase) remains the recommended therapy for acute ischemic stroke. However, several factors are limiting its practical use. It makes it urgent for us to search more efficient strategies that can save the ischemic neurons, and safely extend the time window, while in the mean time reducing the detrimental effects for stroke thrombolysis. Hyperbaric oxygen therapy (HBOT) is considered to be potentially neuroprotective. Co-administration of r-tPA and HBOT has already been proved to be effective, safe and feasible in myocardial infarction. In this article, we would like to review whether HBOT has any beneficial effects on r-tPA thrombolysis. If there is, what is the underlying possible mechanisms and how to optimize for maximal effects?
机译:静脉重组组织型纤溶酶原激活剂(r-tPA,阿替普酶)仍然是急性缺血性卒中的推荐治疗方法。但是,有几个因素限制了它的实际使用。因此,我们迫切需要寻找更有效的策略来节省缺血性神经元,并安全地延长时间范围,同时减少对中风溶栓的有害影响。高压氧疗法(HBOT)被认为具有潜在的神经保护作用。已经证明,r-tPA和HBOT的共同给药在心肌梗塞中是有效,安全和可行的。在本文中,我们将回顾HBOT是否对r-tPA溶栓有任何有益作用。如果有的话,潜在的潜在机制是什么?如何最大程度地优化效果?

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号